Paediatric & Population-Based Dermatology

🌍 Grand Challenges in Global Skin Health Revisited 🌍 academic.oup.com/bjd/advance-ar…

Earlier this month, the TRANS-FOODS Consortium met in Paris, hosted by Dr. Elodie Segura at the Institute Necker Enfants Malades - Inserm, Université Paris.

Back from a packed EADV Congress in Paris! Professor Flohr presented on the latest findings from the UK-Irish A-STAR register and spoke on ‘Atopic Dermatitis in Children’. Catch up on the highlights here: player.vimeo.com/video/11201999…

📓 EADV2025 Book of the Conference! 📓 Delighted to see our Handbook of Skin Disease Management voted as the 'Book of the Conference' at the European Academy of Dermatology and Venereology Congress 2025 in Paris by Wisepress.com.

Congratulations to Stuart Jones, Elodie Segura from the TRANS-FOODS consortium on leading on this Cell publication: Transient skin stretching mimicking skin massage stimulates immune surveillance and promotes vaccine delivery via hair follicles: cell.com/cell-reports/f…

🌍 Making a difference to those living with eczema - join us in celebrating World Eczema Day! Check us out on ppopderm.org to find out more about what we do.

How are the mind and skin connected? 🧠✨🩵 Watch our newest video on the Mind and Skin study here: youtube.com/shorts/r-JOxFV…

Hot off the press: TRANS-FOODS paper shows handwashing removes up to 90% of peanut protein from the skin #peanutallergy #foodallergy #transcutaneoussensitization #atopicdermatitis #eczema

The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children: results from the TREAT trial 🔗 doi.org/10.1093/bjd/lj…

Revisiting our health economic analysis from the TREAT trial published in the British Journal of Dermatology! Methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: an economic evaluation 🔗 doi.org/10.1093/bjd/lj…

We’re excited to share our latest findings from the UK TREAT Trial, now published open access in BJD: Methotrexate and ciclosporin improve skin biomarkers in paediatric atopic dermatitis 🔗 doi.org/10.1093/bjd/lj…

Our 'living' update of the European guideline for the treatment of atopic eczema has just appeared: onlinelibrary.wiley.com/doi/epdf/10.11… A special 'thank you' to all members, in particular co-lead Professor Andreas Wollenberg and the EuroGuiDerm Centre team in Berlin. #eczema #treatment

🌟 We're Hiring! 🌟 guysandstthomas.nhs.uk/current-vacanc…

UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) hits 1000th patient milestone! 🎉 👏 Congratulations to the Norfolk and Norwich team and their colleagues who recruited this patient. 📩 Interested in joining the A-STAR study? Contact us at: a-star@gstt.nhs.uk

Wrapping up an inspiring #ISADSociety conference in #Doha! 🌍 Grateful for the chance to connect, learn and share insights with experts from around the world. Here's to continued collaboration and advancements in dermatology for better patient care everywhere #AtopicDermatitis

Dr Helen Alexander presented at the ISAD conference, providing an overview of the TREAT trial immunology results and highlighting the key finding that MTX and CyA modulate skin and systemic immune markers with MTX showing a more sustained effect after treatment cessation.

🚀 @globalADatlas is making strides in addressing gaps in the global burden map for atopic dermatitis. Check out our latest update for ongoing and upcoming work: atopicdermatitisatlas.org/en/explore-dat… 🌍 #AtopicDermatitis #SkinHealth #EczemaAwarenessMonth #GlobalHealth #Dermatology #Eczema

Professor Carsten Flohr is just back from British Society for Allergy and Clinical Immunology Annual Conference, speaking on biologics in atopic dermatitis and contributing to a panel discussion on multisystem allergic disease.

🏃‍♂️🏃‍♀️ Our Paediatric & Population-Based Dermatology Research Team is taking on the Great South Run to raise funds for the National Eczema Society and support life-changing eczema research! 💙 ajbellgreatsouthrun2024.enthuse.com/pf/popderm 🔗 Link in bio to donate!

🎉 Exciting news! We’ve just recruited the first adolescent in the UK for the COAST-2 clinical trial! This trial uses amlitelimab, an OX-40 ligand monoclonal antibody, to explore new ways to treat atopic dermatitis.